Arrowhead Pharmaceuticals, Inc. (FRA:HDP1)

Market Cap	6.17B
Revenue (ttm)	706.94M
Net Income (ttm)	-1.39M
Shares Out	n/a
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	172
Open	44.51
Previous Close	45.03
Day's Range	44.51 - 44.82
52-Week Range	8.85 - 50.32
Beta	n/a
RSI	66.26
Earnings Date	Nov 26, 2025

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2001
• Employees: 711
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: HDP1

Financial Performance

In 2025, Arrowhead Pharmaceuticals's revenue was $829.45 million, an increase of 23258.15% compared to the previous year's $3.55 million. Losses were -$1.63 million, -99.73% less than in 2024.

Financial numbers in USD